Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT06072859
Other study ID # 00025267
Secondary ID
Status Enrolling by invitation
Phase N/A
First received
Last updated
Start date September 21, 2023
Est. completion date June 30, 2024

Study information

Verified date October 2023
Source Oregon Health and Science University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of the study is to learn about the ease of using a humidified fragrant citrus forest oil, along with a virtual simulation of a forest environment (i.e., with sights and sounds of nature using a personal tablet Surface Pro 3 with headphones, to learn more about how these two aspects of the simulated forest immersion therapy (SFIT) may improve pain, anxiety, blood-pressure, and heart rate related to Axial Spondyloarthritis. The investigators hope to learn how well SFIT may impact pain levels, feelings of calm, as well as blood- pressure and heart rate, and how participants tolerate the experience overall.


Description:

DURATION: Participation in the study will consist of 1 visit total and will last up to 2 consecutive hours. PROCEDURES: Participants will be randomized to receive either the forest oils only, or the forest oils and audio-visual forest exposure described above for up to 1 hour. Study Visit: - During Visit 1 and the only study visit, the investigator will explain the study and obtain consent. The Investigator will explain this study and answer any questions the participant may have. The participant will have the opportunity to review this document in detail. - Consent may be withdrawn by the participant at any time during the study. - Once the written consent is signed, the participant will be asked to rest for 15 minutes. - During the resting period, randomization will occur into one of two groups: - Group 1 - Forest oils only, or - Group 2 - Forest oils and audio-visual forest exposure - Following the resting period, demographics will be collected from the participants. - The investigators will then take a blood pressure and heart rate measurement. - Then, the investigator will ask the participants to fill out two questionnaires. One of these questionnaires consists of two questions asking the participants about their pain level and location, the other questionnaire asks about mood state and how the participants rate various qualities of their feelings. The third questionnaire asks the participants about their pain levels specific to the past week. - Participants will then be taken into the study room where they will participate in the simulated forest experience. - If the participants are randomly assigned to Group 1, they will be breathing in the aroma of the forest oils for a period of 1 hour in the study room. There is an adjustable lounge chair in the room to sit in. And the participants may read or use their phone quietly. - If the participants are randomly assigned to Group 2, they will be breathing in the aroma of the forest oils for a period of 1 hour in the study room while using the headphones and tablet with the simulated forest greenspace sights and sounds. There is an adjustable lounge chair in the room to sit in. - The investigator will take the participants blood pressure and heart rate measurement after 30 minutes from the start of the intervention. - Within 15 minutes following the simulated experience in the study room, the investigator will take one more blood-pressure and heart rate measurement. Then, the participants will fill out the same two questionnaires again, which are asking the participants about their pain level and location and mood. - The investigators will then ask the participants some questions about the participants' experience before the end of the study visit. - One week after the participants study visit (Study Visit 1), the investigator will ask the participants to return two follow-up questionnaires to us over encrypted and password protected OHSU email, or by arranging to drop the questionnaires off with the Study Coordinator or the Rheumatology Clinic at OHSU. RISKS: There are three risks to participation in this study and these are all considered minimal risks. Participants may have an allergic reaction, a cough, or an increase in asthma type symptoms, such as difficulty breathing related to the humidified fragrant citrus forest oil used in this study. For those in Group 2, the participants may experience a sensation of nausea (feeling queasy), discomfort related to the headphone placement, sound disturbances related to the volume of the nature sounds, or discomfort related to viewing the images of the forest greenspace environment utilized in this study. the investigators will make every effort to protect the participants privacy during this study, including password protected files, secure and encrypted email, and double locked file system. A loss of confidentiality happens when the participants private information is accessed outside the scope of this study. A loss of confidentiality is an unexpected event. BENEFITS: Participants may not directly benefit from taking part in this research. However, participation will potentially benefit patients with Axial Spondyloarthritis in the future.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 20
Est. completion date June 30, 2024
Est. primary completion date June 30, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 100 Years
Eligibility Inclusion Criteria: - able to read at a 5th grad level - medically diagnosed with Axial Spondyloarthritis - tolerate having their BP and HR taken - average of greater than 3 on their last recorded pain assessments - average of greater than 4 on their last BASDI recorded - currently have an assigned Rheumatologist in their care delivery Exclusion Criteria: - history of asthma - currently pregnant - inability to detect common odors from commercial fragrances - smoking within 15 minutes of the start of the intervention procedure - known allergy to citrus aroma - hard of hearing without assistive devices - limited vision not corrected by eye lenses - history of hypertension uncontrolled by medications

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Humidified Forest Oils
60mls Limonene in 200mls water humidified with a diffuser.
Virtual Reality using Surface Pro and headphones
Surface Pro has a looped visual that can be manipulated by the participant to simulate walking on a forest path or through a forest visual. This is paired with headphones to experience ambient forest sounds.

Locations

Country Name City State
United States Oregon Health & Science University Portland Oregon

Sponsors (1)

Lead Sponsor Collaborator
Oregon Health and Science University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Axial Skeleton Pain Pain on Visual Analog Scale, Scores 0-10 with higher scores reflecting greater pain before intervention on visit 1, directly after intervention on visit 1, and one week later
Primary Anxiety Anxiety as scored on STAI - State only Higher scores mean greater state anxiety, 20 items with a scoring range of 1-4 on each of them. Score is totaled and range 20-80 with higher scores reflecting higher anxiety as a state. before intervention on visit 1, directly after intervention on visit 1, and one week later
Primary Blood Pressure Blood Pressure measured by Omnicron tabletop BP and HR device, used clinically, higher Blood Pressure, both systolic and diastolic pressures, measured reflect/correlate with higher anxiety or pain status. Measure range 0-240. before intervention on visit 1, after 30 minutes of the intervention start on visit 1, directly after intervention on visit 1, and one week later
Primary Heart Rate Heart Rate measured by Omnicron tabletop BP and HR device, used clinically, higher Heart Rate measured reflect/correlate with higher anxiety or pain status. Measure range 0-300. before intervention on visit 1, after 30 minutes of the intervention start on visit 1, directly after intervention on visit 1, and one week later
Primary Feasibility Questions Questions regarding the intervention include the tolerance of the intervention, likes and dislikes of the experience and any suggestions to make the intervention experience better. directly after intervention on visit 1
Secondary Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Measures pain and functionality in Axial Spondyloarthritis by assessing individual metrics for fatigue, axial involvement, peripheral articular involvement, localized tenderness/enthesitis, and morning stiffness. Score 0-10 with higher scores reflecting higher pain and functionality issues. before intervention on visit 1, directly after intervention on visit 1, and one week later
Secondary Routine Assessment of Patient Index Data 3 (RAPID3) composite index which is routinely and reliably used to assess disease activity in Axial Spondyloarthritis. Score range 0-30 with higher scores reflecting higher disease activity. before intervention on visit 1, directly after intervention on visit 1, and one week later
See also
  Status Clinical Trial Phase
Completed NCT05031767 - Remote Monitoring of Axial Spondyloarthritis N/A
Completed NCT05162937 - to Evaluate the Preliminary Efficacy and Safety of GR1501 Injection in Patients With Active Axial Spondyloarthritis Phase 2
Completed NCT03622658 - Efficacy and Safety of Namilumab for Moderate-to-severe Axial Spondyloarthritis Phase 2
Completed NCT03248518 - Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases N/A
Terminated NCT02437162 - A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNFα Naive Participants With Active Radiographic Axial Spondyloarthritis Phase 3
Completed NCT02552212 - Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS Phase 3
Active, not recruiting NCT01944163 - The IMPACT of a Referral Model for Axial Spondyloarthritis in Young Patients With Chronic Low Back Pain N/A
Active, not recruiting NCT02687620 - Does Immunogenicity Have an Influence on the Efficacy of Anti-TNF Therapy in Patients With AS: An Inception Cohort Study
Completed NCT00844805 - Infliximab for Treatment of Axial Spondyloarthritis (P05336 AM1) Phase 3
Terminated NCT02897115 - A Study Treating Participants With Early Axial Spondyloarthritis (axSpA) Taking an Intense Treatment Approach Versus Routine Treatment Phase 4
Completed NCT05019547 - The Turkish Version of the Inflammatory Arthritis Facilitators and Barriers to Physical Activity
Recruiting NCT03738956 - Safety and Efficacy of Tofacitinib in the Treatment of NSAID Refractory Axial Spondyloarthritis:A Clinical Trial Phase 2/Phase 3
Completed NCT04679649 - Physiotherapy of Axial Spondyloarthritis N/A
Enrolling by invitation NCT02962479 - Is the Human Microbiome Altered in Patients With Axial Spondyloarthritis? N/A
Completed NCT04485078 - Investigation of Central Sensitization Frequency and Related Factors in Axial Spondyloarthritis Patients
Recruiting NCT05812157 - Optimizing Anti-IL17 Antibody Therapy by Associating Fiber Supplementation to Correct Treatment-aggravated Gut Dysbiosis in Axial Spondyloarthritis - RESPOND-IL17 N/A
Completed NCT03039088 - PREDICT-SpA - French Epidemiological Study of the Evaluation of the Impact of Fibromyalgia in the TNF Alpha Treatment Effect in Axial Spondyloarthritis in Both Anti-TNF naïve and - Experienced Patients
Completed NCT04368494 - Exercise Therapy in Patients With Axial Spondyloarthritis N/A
Completed NCT03270501 - Efficacy of Golimumab in Early Axial Spondyloarthritis in Relation to Gut Inflammation Phase 3
Completed NCT03043846 - Treat to Target Trial in Axial Spondylo Arthritis : The TICOSPA (Tight Control in Spondyloarthritis)